A Study of LY2928057 in Hemodialysis Participants

Inclusion Criteria:

- Participants having end-stage renal disease (ESRD), have received an erythropoiesis
stimulating agent (ESA) at least weekly for 2 weeks prior to screening, and have been
receiving adequate maintenance hemodialysis (3 times weekly) for at least 12 weeks
prior to screening (that is, an approximate Kt/V greater than 1.1 (K equals dialyzer
clearance of urea, t equals dialysis duration time, V equals volume of distribution of
urea, which is approximately equal to the participant's total body water) based on the
clinical judgment of participant's nephrologist and investigator and who are willing
to stop (Parts A and B) or reduce (Part C) their stable ESA dose from the week of
randomization until completion of the 6-week treatment period (unless rescue therapy
is needed)

- Have a hemoglobin value (taken prior to dialysis if taken on a dialysis day) greater
than or equal to 9.5 grams per deciLiter (g/dL) and less than or equal to 12.5 g/dL at
screening

- Have a body mass index (BMI) of 18.5 to 45 kilograms per square meter (kg/m^2)
inclusive at screening

- Have a transferrin saturation (TSat) greater than or equality to 15 percent and
ferritin greater than 40 nanograms per milliliter (ng/mL) at screening

Exclusion Criteria:

- Any cause of anemia other than renal disease

- A history of hyporesponsiveness to ESA